Oncology field sales

[anonymous]

I was thinking of applying to a Novartis oncology position. Can anyone share the culture in that division? I have some friends across the country who work in the cardiovascular and MS areas and they said it’s nothing but micromanagement, call metrics with unrealistic numbers, bad sales data and a lot of field rides. Is it similar in oncology? Thank you for any information.

 

[anonymous]

Uh…
YES!

 

[anonymous]

Sadly, the only place with good culture here continues to be in Rheumatology.

 

[anonymous]

Customer engagement is running this place like we are primary care. Everyone gets a laptop, iPad, company phone. Success. Hard pass unless you’re desperate.

 

[anonymous]

Thank you for the honest feedback. How can they run oncology like primary care? Really sad to hear this

 

[anonymous]

Sadly, the only place with good culture here continues to be in Rheumatology.

Do you think the new product for allergy will be run like Rheumatology? It’s a lot of cosentyx folks.. trying to decide if I should go for it

 

[anonymous]

I love it when the offices eat their lunch

 

[anonymous]

Do you think the new product for allergy will be run like Rheumatology? It’s a lot of cosentyx folks.. trying to decide if I should go for it

Why would you leave the cushy Cosentyx team to sell remi? New scripts are going to be harder to uncover than legal votes for Biden. BID?, no thanks and 90% of allergists will continue to use Xolair for CSU, one because they’ll buy and bill it until the day they can’t and two, I’m sure it won’t work as well as a xolair either, see ligelizumab. And forget about your relationship w derms, most are idiots and could care less if their patients are itchy.

 

[anonymous]

Do you think the new product for allergy will be run like Rheumatology? It’s a lot of cosentyx folks.. trying to decide if I should go for it

Why would you leave the cushy Cosentyx team to sell remi? New scripts are going to be harder to uncover than legal votes for Biden. BID?, no thanks and 90% of allergists will continue to use Xolair for CSU, one because they’ll buy and bill it until the day they can’t and two, I’m sure it won’t work as well as a xolair either, see ligelizumab. And forget about your relationship w derms, most are idiots and could care less if their patients are itchy.

 

[anonymous]

Why would you leave the cushy Cosentyx team to sell remi? New scripts are going to be harder to uncover than legal votes for Biden. BID?, no thanks and 90% of allergists will continue to use Xolair for CSU, one because they’ll buy and bill it until the day they can’t and two, I’m sure it won’t work as well as a xolair either, see ligelizumab. And forget about your relationship w derms, most are idiots and could care less if their patients are itchy.

Dupixent will likely have a CSU indication as well by the end of the year. Remi will be a very hard sell to specialists for the most part. I can see the company having reps visit primary care offices as well since remi is a pill. They can prescribe it so easily before having to refer out to a specialist

 

[anonymous]

What are call expectations or metrics per day/week for oncology? I’m with a smaller company where we don’t track metrics or call activity and we are allowed to record email and nurse interactions as calls on physicians. Any insight is appreciated as I am interviewing and don’t want to make a wrong move

 

[anonymous]

Dupixent will likely have a CSU indication as well by the end of the year. Remi will be a very hard sell to specialists for the most part. I can see the company having reps visit primary care offices as well since remi is a pill. They can prescribe it so easily before having to refer out to a specialist

Dupixent will definitely not have a CSU indication by the end of the year but agree on Remi being a very hard sell.

 

[anonymous]

Dupixent will definitely not have a CSU indication by the end of the year but agree on Remi being a very hard sell.

not to mention dupi’s efficacy in CSU is laughable...can’t even believe they are still pursuing the indication, frankly. It’s weakness in CSU will actually have a negative halo effect for other indications, IMO.

 

[anonymous]

What are call expectations or metrics per day/week for oncology? I’m with a smaller company where we don’t track metrics or call activity and we are allowed to record email and nurse interactions as calls on physicians. Any insight is appreciated as I am interviewing and don’t want to make a wrong move

Just do your job and sell product. There is no call average. Lose the primary care mentality, this is real sales!

 

[anonymous]

Dupixent will definitely not have a CSU indication by the end of the year but agree on Remi being a very hard sell.

Remi will be a hard sell. The company is overestimating its potential.

 

[anonymous]

Remi will be a hard sell. The company is overestimating its potential.

What else is new…..

 

[anonymous]

What are call expectations or metrics per day/week for oncology? I’m with a smaller company where we don’t track metrics or call activity and we are allowed to record email and nurse interactions as calls on physicians. Any insight is appreciated as I am interviewing and don’t want to make a wrong move

 

[anonymous]

Expectation 5.8 calls per day
Zero call days tracked too
80% reach on tier 1 & 2

 

[anonymous]

Expectation 5.8 calls per day
Zero call days tracked too
80% reach on tier 1 & 2

Thank you for sharing. I have never heard of such high call expectations for oncology and that’s a ridiculous metric for reach on top tiers. Does anyone actually meet objectives and are they closely tracked?